IOncology

From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC) was held with great success. During the conference, the Chinese Society of Clinical Oncology (CSCO) and SGBCC jointly organized the "Voice of China" session, showcasing China's advancements in clinical research, basic science, translational medicine, and radiomics within the breast cancer field, which sparked vibrant discussions among global experts. “Oncology Frontier” invited the co-chairs of this session—Prof. Zefei Jiang (St.Gallen International Consensus panel Member, CSCO President-Elect, Chinese PLA General Hospital) and Prof. Michael Gnant (SGBCC Conference Chair, Comprehensive Cancer Center, Medical University of Vienna)—to engage in a profound dialogue on the future of Sino-global collaboration.

In a multicenter observational study across 12 Italian oncology units, Dr. Alessandra Fabi and colleagues evaluated the real-life effectiveness of Trastuzumab Deruxtecan (T-DXd) in 39 patients with HER2-positive breast cancer…

At #EAU25, Dr.Nikhil Mayor (Imperial College London) presented results from the NeuroSAFE PROOF trial (NCT03317990)—the first randomized, controlled, single-blinded study comparing NeuroSAFE-guided versus standard robot-assisted radical prostatectomy (RARP) in localized…

At #EAU25, Dr. Ricardo Almeida Magana (UCL, London) presented compelling data from the NeuroSAFE PROOF trial, a multicenter, randomized phase 3 study evaluating the role of intraoperative frozen section analysis…

At #EAU25, Dr. Giulio Francolini and colleagues presented early results from the ongoing PERSIAN trial (NCT03449719) a randomized phase II study investigating the addition of stereotactic body radiotherapy (SBRT) to…

At #EAU25, Dr. Fred Saad presented new insights from the PEACE-3 trial (NCT02194842), a multicenter study evaluating enzalutamide ± radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) and bone…

For patients with non-muscle invasive bladder cancer (NMIBC), transurethral resection of bladder tumor (TURBt) and intravesical instillation remain the mainstays of treatment. However, a subset of high- or very high-risk…

The 19th St. Gallen Breast Cancer Conference (SGBCC), held in Vienna from March 12 to 15, 2025, remains one of the most influential global platforms in early breast cancer care. Among seven studies awarded the prestigious Best Poster Award, four came from China, including a multi-center real-world study led by Professor Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences. Her research focused on treatment-insensitive HER2-positive breast cancer patients undergoing neoadjuvant therapy. Oncology Frontier spoke with Professor Fan to learn more about the study’s results, and broader implications.

Prostate cancer remains one of the most prevalent malignancies threatening men’s health worldwide. A major research focus today lies in developing accurate screening and diagnostic strategies that minimize the invasiveness and psychological burden of biopsy procedures. Landmark studies like SMART and PRECISION aim to address these challenges. At the 2025 European Association of Urology (EAU) Annual meeting, Professor Chiu Ka Fung Peter from the Department of Urology at The Chinese University of Hong Kong presented the latest findings from the SMART study. Following his presentation, Professor Chiu spoke with UroStream to share key updates in prostate cancer diagnostics and care.

The 2025 South-North Forum – 7th Breast Cancer forum was recently held in Shanghai, co-hosted by the Shanghai Anti-Cancer Association and the China Anti-Cancer Association Committe of Breast Cancer Society(CACA-CBCS), with support from the Chinese Medical Association, Chinese Society of Oncology- Breast Oncology(CMA-CSO-BO). The event was co-organized by Fudan University Shanghai Cancer Center and The First Affiliated Hospital of China Medical University. Upholding the values of openness, collaboration, and innovation, the forum has emerged as a dynamic hub of academic exchange in breast cancer research. Oncology Frontier invited Prof. Jin Feng, chair of the forum and a leading figure from The First Affiliated Hospital of China Medical University, to reflect on the forum’s milestones, key highlights, and its role in nurturing the next generation of clinical scholars.